CLLS vs ORGO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CLLS shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
ORGO presents a stark contradiction between explosive growth and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 2/9. While the company shows massive YoY revenue (78.1%) and earnings growth (555.2%) and trades below both its Graham Number ($2.92) and Intrinsic Value ($4.72), the technical trend is severely bearish (0/100). The strong liquidity ratios and low debt/equity are offset by the poor F-Score and a 1-year price decline of nearly 40%. Consequently, the stock is a high-risk value play where growth potential is currently overshadowed by fundamental instability.
Compare Another Pair
Related Comparisons
CLLS vs ORGO: Head-to-Head Comparison
This page compares Cellectis S.A. (CLLS) and Organogenesis Holdings Inc. (ORGO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.